ICOTYDE (icotrokinra) - (ICONIC-LEAD)

Oct. 9, 2026: Johnson & Johnson (NYSE: JNJ) reported two-year Phase 3 ICONIC-LEAD data for ICOTYDE (icotrokinra) in adults and adolescents aged 12+ with moderate-to-severe plaque psoriasis, presented at Fall Clinical Dermatology 2026. At Week 112, at least 72% of ICOTYDE-treated patients achieved PASI 90 and at least 70% achieved IGA 0/1 from Week 64 through Week 112; complete clearance was sustained with at least 44% achieving PASI 100 and at least 46% achieving IGA 0. Clinically meaningful itch improvement was sustained in 78% of patients from Week 64 to Week 112. Among PASI 90 responders withdrawn from treatment at Week 24, 85% regained PASI 90 within 24 weeks of retreatment. No new safety signals were identified through Week 112.

ICONIC-LEAD enrolled 684 patients, including 66 adolescents, and used PASI 90 and IGA 0/1 with at least a 2-grade improvement as co-primary endpoints.

The company also said the Phase 3 ICONIC program includes ICONIC-TOTAL, ICONIC-ADVANCE 1, and ICONIC-ADVANCE 2 in plaque psoriasis, with additional ongoing studies in psoriatic arthritis (ICONIC-PsA 1/2), ulcerative colitis (ICONIC-UC), and Crohn’s disease (ICONIC-CD).